Alnylam's (ALNY) Strong ALN-PCSsc Data at AHA Conference, FBR Capital Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at American Heart Association Meeting Confirm Potential for Bi-Annual Hypercholest
November 11, 2015 10:45 AM ESTUp to 53 percent Maximal and 47 percent Least Squares Mean Reduction in LDL-C Achieved at 6 Months after Single, Low-Volume, Subcutaneous Injection
ALN-PCSsc Also Achieves Major Reductions in Other Atherogenic Lipids, Including Lowering of Lp(a) and Total Cholesterol of up to 77 percent and 55 percent, Respectively
Companies On Track to Initiate ORION-1 Phase 2 Trial by End-2015
Companies to Host Conference Call Today at 4:30 p.m.
CAMBRIDGE, Mass. & PARSIPPANY, N.J.--(BUSINESS WIRE)--... More
